Restenosis, the recurrence of narrowing of the arteries after stenting, is a common risk of this endovascular treatment. There are no well-defined guidelines to treat restenosis, but recent studies have shown excellent results with drug-eluting balloon angioplasty in coronary and femoral artery stents. However, few studies have focused on the carotid arteries, which take blood to the neck and head.

Doctors are more likely to try a new therapy when they are persuaded to do so by an influential colleague, reports a new Northwestern University study whose findings on adopting innovations also have relevance for business, education and research.

If Marvelā€™s Captain America can lay still during a magnetic resonance imaging (MRI) exam, so can kids. Thatā€™s the message of a special comic book designed to ease childrenā€™s fears before they undergo a scan, which requires them to lay still in a narrow, loud machine in order for it to produce clear images. The new Marvel Custom Solutions comic book is included in an ā€œMRI Heroes Kitā€ developed by Siemens Healthcare and Marvel Custom Solutions in collaboration with Weill Cornell Imaging at NewYork-Presbyterian and Weill Cornell Medical College. The kit is designed to empower young patients by educating them about the procedure in a gentle and compelling way.

Mindray introduced the M9 premium compact ultrasound system at theĀ American College of Emergency Physicians (ACEP) annual meetingĀ , the next generation in point-of-care ultrasound technology. The M9 is designed to provide physicians imaging for immediate clinical management and decision-making.

Topera, Abbott, FIRMap, rotors, rotor mapping
Topera, Abbott, FIRMap, rotors, rotor mapping
Topera, Abbott, FIRMap, rotors, rotor mapping

Abbott has entered into an agreement to purchase Topera Inc., a private, venture-backed medical device company focused on developing electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation (AF). Through this acquisition, Abbott enters the catheter-based electrophysiology (EP) market, an approximately $3 billion global market that has been growing annually at double-digit rates.

Sorin Group announced today a $20 million minority investment in Respicardia, a developer of implantable therapies to improve Respiratory Rhythm Management. Under the terms of the transaction, Sorin also acquired the exclusive right to distribute theĀ remed? System for the next five years in selected countries in Europe and an exclusive option to acquire Respicardia in the future. Respicardia is based in Minneapolis.

Subscribe to
Ā© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now